All Penny Stocks.com News: Cellceutix Phase 2 Trial Preliminary Data Shows Potential of Brilacidin

Mississauga, ON -- (SBWIRE) -- 10/11/2016 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Cellceutix Phase 2 Trial Preliminary Data Shows Potential of Brilacidin."

Companies mentioned in this article include iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and Cellceutix Corp. (OTCQB:CTIX).

Article Excerpt:

The biotech sector has been in a short term downtrend over the last few weeks, however, the sentiment on the sector remains mixed. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has struggled to break through $300 since the sell-off at the start of this year.

The IBB got a boost recently following the announcement of several acquisitions. However, these acquisitions were made at discount to the price levels in mid-2015 when the biotech sector was in the middle of a boom. At best, these acquisitions would provide support to the sector, however, the IBB is likely to remain rangebound.

Shares of Cellceutix Corp. (OTCQB:CTIX) have edged higher in recent days, moving in the opposite direction of the overall biotech sector. Based in Beverly, Massachusetts, Cellceutix is a clinical-stage biopharmaceutical company engaged in developing therapies with oncology, dermatology and antimicrobial applications. The company owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/678/cellceutix-phase-2-trial-preliminary-data-shows-potential-of-brilacidin.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999.

Investors can receive their free newsletter subscription by clicking here:
http://www.allpennystocks.com/aps_common/newsletter_free.asp

Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp

For more information on this press release visit: http://www.sbwire.com/press-releases/all-penny-stockscom-news-cellceutix-phase-2-trial-preliminary-data-shows-potential-of-brilacidin-731240.htm

Media Relations Contact

Peter Szafranski
Telephone: 905-361-5680
Email: Click to Email Peter Szafranski
Web: http://www.allpennystocks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X